R547

製品コードS2688 バッチS268801

印刷

化学情報

Chemical Structure Synonyms Ro 4584820 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C18H21F2N5O4S
分子量 441.45 CAS No. 741713-40-6
Solubility (25°C)* 体外 DMSO 60 mg/mL (135.91 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.
in vitro R547 identified as a diaminopyrimidine compound, which is a potent and selective ATP-competitive CDK inhibitor. R547 effectively inhibits CDK1/cyclinB, CDK2/cyclinE, and CDK4/cyclinD1(Ki=1-3nM) and is inactive(Ki>5,000nM) against a panel of >120 unrelated kinases. R547 effectively inhibits the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC50s <0.60 μM. R547 reduces phosphorylation of the cellular retinoblastoma protein at specific CDK phosphorylation sites at the same concentrations that induced cell cycle arrest, suggesting a potential pharmaco dynamics marker for clinical use. R547 inhibits the proliferation of tumor cell lines and is active in all 19 cell lines tested irrespective of tissue of origin, multidrug resistance (MDR), p53, or retinoblastoma status. [1] R547 possessing both 5-and 6-fluoro substitution culminated in an Inhibitor with low, single-digit nanomolar potency against the CDKs(Ki=0.001,0.003,and 0.001 μM for CDK1,CDK2, and CDK4,respectively) and excellent cellular potency (IC50=0.08 μM,HCT116 cell line). [2]
in vivo R547 administered with oral and i.v. dosing in multiple established human tumor significantly inhibits tumor activity(P < 0.01). R547 administered orally at dose of 40 mg/kg daily in colon, lung, breast, prostate, and melanoma human tumor xenograft models shows significant TGI (79-99%). R547 is equally efficacious (TGI, 61-95%) when dosed with 40 mg/kg i.v. once weekly. These doses of R547 are not toxic and did not result in body weight loss. R547 does not show signs of overt toxicity during the course of the 3-week study and any gross pathology at necropsies done at the end of the studies. [1] R547 inhibits tumor growth up to 95% in the HCT116 human colorectal tumor xenograft model in nude mice . R547 causes significant TGI in all of the models tested when dosed orally and i.v. at or below the maximum tolerated dose. R547 inhibits phosphorylation of retinoblastoma protein in tumors at the efficacious exposures in tumor xenograft models, providing a pharmacodynamic biomarker for clinical use. R547 reported here suggests that this is a promising molecule for evaluation in the treatment of solid tumors. [2]

プロトコル(参考用のみ)

キナーゼアッセイ Kinase Assays
Enzyme reactions are initiated by adding recombinant histidine-tagged enzyme and retinoblastoma substrate to 384-well plates containing diluted test compounds. Final reaction conditions are such that the ATP concentration is 3× the respective enzyme Km for ATP in the presence of 25 mM HEPES (pH 7.0), 6.25 mM MgCl2, 1.5 mM DTT, 0.002% Tween 20, and 0.2 mg/mL bovine serum albumin (BSA). After a 25-minute incubation at 37 °C, reactions are terminated by addition of anti-phosphorylated retinoblastoma (Ser780) antibody. The phosphorylated retinoblastoma is analyzed by adding lance europium anti-rabbit IgG and anti-his- allophycocyanin, resulting in fluorescence resonance energy transfer between europium anti-rabbit and allophycocyanin, and quantified by fluorescence intensity ratio 665 nm/615 nm (excited at 340 nm). IC50s are calculated from net readings at 665 nm, normalized for europium readings at 615 nm. The kinase insert domain-containing receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, and epidermal growth factor receptor kinase assays are also homogeneous time-resolved fluorescence assays. Protein kinase A, protein kinase B, protein kinase Cα, protein kinase Cβ, FYN, extracellular signal-regulated kinase 2, p38, mitogen-activated protein kinase 2,serum/glucocorticoid-regulated kinase, and EPHB3 assays are conducted using an assay based on IMAP Technology that enables quantitation of kinase activity via preferential binding of phosphorylated fluorescent peptide substrates to immobilized metal beads. These reactions are carried out at ATP concentrations of 3× the Km for the respective enzyme. SRC, focal adhesion kinase, AURORA, glycogen synthase kinase (GSK) 3β, and insulin-like growth factor receptor kinase assays are fluorescence resonance energy transfer assays run at the Km for ATP. R547 is also evaluated for activity against 123 kinases at a single 10 μM concentration in the Upstate kinase selectivity screen and the IC50s determined in the Upstate IC50 Profiler Express for kinases identified as hits in the initial screen.
動物実験 動物モデル female nude mice bearing established HCT116 human colorectal xenografts with a mean starting volume of about 100 mm3
投薬量 25 ,50,75 mg/kg
投与方法 Orally three times per week on Monday, Wednesday, and Friday for 18days

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia [ Cancer Cell, 2022, S1535-6108(22)00312-9] PubMed: 35868306
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] PubMed: 32645325
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] PubMed: 32645325
Cell cycle-dependent phosphorylation of PRPS1 fuels nucleotide synthesis and promotes tumorigenesis [ Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486] PubMed: 31253668
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. [ Oncotarget, 2018, 9(41):26353-26369] PubMed: 29899864
A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. [ Cell Rep, 2017, 18(13):3167-3177] PubMed: 28355568

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。